WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced detailed analyses from the Phase 3 C-POST trial, which evaluated PD-1 inhibitor Libtayo (cemiplimab)in patients with high-risk cutaneous squamous cell carcinoma after surgery.
The results include additional data for the primary endpoint of disease-free survival (DFS) and the first presentation of key secondary endpoint outcomes.
The Phase 3 C-POST trial demonstrates that cemiplimab is a highly active therapy in high-risk cutaneous squamous cell carcinoma, with clinically meaningful outcomes across primary and secondary endpoints and exceptionally low rates of locoregional and distant recurrence.
The company noted that Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial. Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to placebo.
For More Such Health News, visit rttnews.com.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
